The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry

• Published in: The lancet oncology Vol. 24; no. 6; pp. 701 - 708
• Main Authors: Chu, Tian, Meng, Yifan, Wu, Ping, Li, Zheng, Wen, Hao, Ren, Fang, Zou, Dongling, Lu, Huaiwu, Wu, Lingying, Zhou, Shengtao, Chen, Ying, Li, Jundong, Xu, Miaochun, Wu, Xiaoliu, Xiong, Xi, Wang, Zhibin, He, Misi, Zhang, Yuanyuan, Lin, Shitong, Cao, Canhui, Ding, Wencheng, Chen, Yu, Zhi, Wenhua, Peng, Ting, Wei, Ye, Liu, Binghan, Xu, Yashi, Ma, Ding, Wang, Jing, Sun, Chaoyang, Wu, Peng
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2023; Elsevier Limited
• Subjects: Age; Cancer therapies; Carcinoma, Small Cell - epidemiology; Carcinoma, Small Cell - pathology; Carcinoma, Small Cell - therapy; Cervical cancer; Cervical carcinoma; Cervix; Chemotherapy; Clinical outcomes; Diagnosis; East Asian People; Epidemiology; Female; Hematology, Oncology, and Palliative Medicine; Hospitals; Humans; Lymphatic system; Medical prognosis; Medical records; Medical screening; Neoplasm Staging; Patients; Prognosis; Radiation therapy; Registries; Regression analysis; Retrospective Studies; Risk factors; SEER Program; Surgery; Tumors; Uterine Cervical Neoplasms - epidemiology; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - therapy; Variables; China
• DOI: 10.1016/S1470-2045(23)00185-7
• ISSN: 1470-2045; 1474-5488

Small cell carcinoma of the cervix is a rare but poor prognosis pathological type of cervical cancer, for which advice in clinical guidelines is unspecific. We therefore aimed to investigate the factors and treatment methods that affect the prognosis of patients with small cell carcinoma of the cervix. In this retrospective study, we collected data from the Surveillance, Epidemiology, and End Results (SEER) 18 registries cohort and a Chinese multi-institutional registry. The SEER cohort included females diagnosed with small cell carcinoma of the cervix between Jan 1, 2000, and Dec 31, 2018, whereas the Chinese cohort included women diagnosed between Jun 1, 2006, and April 30, 2022. In both cohorts, eligibility was limited to female patients older than 20 years with a confirmed diagnosis of small cell carcinoma of the cervix. Participants who were lost to follow-up or those for whom small cell carcinoma of the cervix was not the primary malignant tumour were excluded from the multi-institutional registry, and those with an unknown surgery status (in addition to those for whom small cell carcinoma of the cervix was not the primary malignant tumour) were excluded from the SEER data. The primary outcome of this study was overall survival (length of time from the date of first diagnosis until the date of death from any cause, or the last follow-up). Kaplan-Meier analysis, propensity score matching, and Cox-regression analyses were used to assess treatment outcomes and risk factors. 1288 participants were included in the study; 610 in the SEER cohort and 678 in the Chinese cohort. Both univariable and multivariable Cox regression analysis (SEER hazard ratio [HR] 0·65 [95% CI 0·48–0·88], p=0·0058; China HR 0·53 [0·37–0·76], p=0·0005) showed that surgery was associated with a better prognosis. In subgroup analyses, surgery remained a protective factor for patients with locally advanced disease in both cohorts (SEER HR 0·61 [95% CI 0·39–0·94], p=0·024; China HR 0·59 [0·37–0·95]; p=0·029). Furthermore, the protective effect of surgery was observed among patients with locally advanced disease after propensity score matching in the SEER cohort (HR 0·52 [95% CI 0·32–0·84]; p=0·0077). In the China registry, surgery was associated with better outcomes in patients with stage IB3-IIA2 cancer (HR 0·17 [95% CI 0·05–0·50]; p=0·0015). This study provides evidence that surgery improves outcomes of patients with small cell carcinoma of the cervix. Although guidelines recommend non-surgical methods as first-line treatment, patients with locally advanced disease or stage IB3-IIA2 cancer might benefit from surgery. The National Key R&D Program of China and the National Natural Science Foundation of China.